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Psoriasis is now classified as an immune-mediated
inflammatory disease (IMID) of the skin. It is being
recognized that patients with various IMIDs, including
psoriasis, are at higher risk of developing ‘‘systemic’’
co-morbidities, e.g., cardiovascular disease (CVD),
metabolic syndrome, and overt diabetes. In non-
psoriatic individuals, the pathophysiology of obesity,
aberrant adipocyte metabolism, diabetes, and CVDs
involves immune-mediated or inflammatory path-
ways. IMIDs may impact these co-morbid conditions
through shared genetic risks, common environmental
factors, or common inflammatory pathways that are
co-expressed in IMIDs and target organs. Given that
pathogenic immune pathways in psoriasis are now
well worked out and a large number of inflammatory
mediators have been identified in skin lesions, in this
review we will consider possible mechanistic links
between skin inflammation and increased risks of
(1) obesity or metabolic alterations and (2) CVD. In
particular, we will discuss how well-established risk
factors for CVD can originate from inflammation in
other tissues.
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INTRODUCTION
Psoriasis vulgaris is a prototypical Th-1, Th-17, and Th-22
inflammatory disease. It is characterized by expansion and
activation of Th-1, Th-17, and Th-22 T cells, with production of
associated cytokines such as interferon-g, tumor necrosis factor
(TNF), IL-17, and IL-22 in the skin (Lowes et al., 2008; Nograles
et al., 2009). In turn, T-cell activation is likely to be controlled
by an extensive array of dendritic antigen-presenting cells that
are also increased in the skin. Myeloid dendritic cells in
psoriasis produce high levels of IL-23 and they strongly
stimulate T-cell proliferation in vitro. One type of dendritic
cell in psoriasis, the TNF-a/inducible nitric oxide synthase
(i-NOS)-producing dendritic cells, produces high levels of TNF,
IL-20, and other inflammatory molecules (Lowes et al., 2007).
As such, this cell could be a key driver of ‘‘innate’’
inflammation, inducing a much wider range of inflammatory
molecules in keratinocytes (KCs) or other cell types through
TNF- and IL-20-driven pathways. Hence, excess production of
IL-1, IL-6, IL-8, vascular endothelial growth factor (VEGF), and
numerous chemokines may originate from this pathway. The
range of inflammatory molecules produced in psoriasis lesions
is also strongly regulated by Th1 and Th17 T cells, as interferon-
g, IL-17, and IL-22 each induce a characteristic array of
inflammatory products in KCs and other cell types present in
psoriasis skin lesions (Nograles et al., 2008). Overall, a vast
range of inflammatory products (hundreds of individual gene
products as identified on gene arrays) are produced in psoriasis
skin lesions and many of these appear to be released into the
systemic circulation as a function of severity and extent of skin
lesions (Liu et al., 2007). Furthermore, effective treatment of
psoriasis reduces the levels of circulating cytokines such as TNF
and IL-1, which, at higher sustained levels, are likely risk factors
for cardiovascular disease (CVD) (Zaba et al., 2007).
A central theme in CVD relates to inflammation as a
risk factor for progressive development of atheroma and
other vascular alterations. Fisman et al. (2003) put forward
the concept of good, bad, and indifferent interleukins
for cardiovascular risk, with the recognition that CVD has
been linked to increased expression of specific interleukins
by epidemiological and/or experimental studies. Figure 1
presents a modification of the Fisman model that has been
updated to include a broader classification of inflammation-
associated molecules that affect the cardiovascular risk,
including cytokines that are not named as interleukins and
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hormones (adipokines) that originate from adipose tissues. In
our model, some cytokines have been re-classified as ‘‘bad’’
based on new experimental evidence or new risk data.
Figure 1 is by no means a comprehensive listing of all
mediators with cardiovascular or metabolic effects, but it
serves as an organizing principle for the subsequent discus-
sion. Although this model is useful to conceptualize a
complex array of cardiovascular risk factors, it does not serve
well to indicate the cellular and tissue beds that produce
cytokines with altered levels in the systemic circulation.
Hence, as shown in Figure 2, in this review we have
classified risk-associated molecules that may be produced
within different organs or tissues and discussed factors that
regulate production.
During periods of active disease, systemic release of
specific cytokines or exposure of leukocytes to skin-derived
inflammation factors while circulating through the inflamed
cutaneous vasculature could alter the properties of circulating
leukocytes or affect endothelial cells at distant sites, e.g., by
inducing expression of ICAM or other adhesion molecules
(Figure 2). There are potential interactions of many inflam-
matory products synthesized in psoriasis skin lesions with
adipose tissue and cardiovascular tissues that are discussed in
the following sections. The skin (hypodermis) contains many
of the adipocytes that are expanded in obese psoriasis
patients and increased numbers of macrophages in psoriasis
lesions extend (at least) to the dermal or adipose interface;
hence, there may be direct interchange of inflammatory cells
and molecules between skin compartments that drive obesity
and alter normal metabolic functions as a consequence of
psoriasis activity. This concept is presented in Figure 3 and
specific ‘‘at-risk’’ molecules are discussed in the next section.
INFLAMMATORY MOLECULES AND PATHWAYS IN
OBESITY
Epidemiological studies indicate that obesity leads to a
higher risk of developing psoriasis and a poorer long-term
clinical outcome of psoriasis. Furthermore, losing weight may
improve psoriasis (Higa-Sansone et al., 2004; Naldi et al.,
2005; Wolters, 2005). In addition, several case studies have
shown that weight loss from gastric bypass surgery results
in remission of psoriasis (Moll et al., 1974; de Menezes
Ettinger et al., 2006). Likewise, a recent controlled study
showed that moderate weight loss (i.e. 5–10% of the body
weight) increases the therapeutic response to a low dose
of cyclosporine in obese patients with moderate-to-
severe chronic plaque psoriasis, suggesting that lifestyle
modifications, including a low-calorie diet, may supplement
the pharmacological treatment administered to obese
psoriasis patients (Gisondi et al., 2008), further supporting
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Figure 2. ‘‘Vicious circle of inflammation’’: mediators of inflammation produced in different organs or tissues are released into the systemic circulation
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the relevance of obesity to psoriasis. Moreover, the ‘‘obesity
of psoriasis’’ is thought to be a key link to excess diabetes
risk and to the metabolic syndrome, as well as contributing
to excess cardiovascular risk. What might be the inter-
relationships?
In addition to energy storage and lipid synthesis produc-
tion, adipose tissue is an active endocrine organ with many
secretory products, including adipocyte-derived hormones,
adipokines, and a variety of proinflammatory cytokines,
including IL-6 and TNF-a. Adipokines are proteins produced
mainly by adipocytes. Although adipose tissue secretes a
variety of factors, many of which are still to be fully
characterized, we will focus only on leptin and adiponectin,
which are primarily produced by adipocytes and for which
most data exist.
Moreover, the adipose tissue is now recognized as a part
of the innate immune system and adipocytokines have
an important role in the pathogenesis of insulin resistance
and are associated with metabolic complications such as
dyslipidemia, hypertension, and premature heart disease
(Rasouli and Kern, 2008).
Adipose tissue is composed of many cell types, but mainly
of adipocytes and the stromo-vascular fraction, which
includes macrophages. Although adipocytes and macro-
phages are derived from a common mesothelial origin, it is
not clear whether preadipocytes can differentiate into
macrophages. In fact, in mice it was shown that the
macrophages in adipose tissue are bone marrow derived
(Weisberg et al., 2003). In obesity, leptin (an adipokine) and
possibly other factors produced by adipocytes, macrophages,
or both upregulate adhesion molecules on endothelial cells
such as ICAM-1 and platelet–endothelial cell adhesion
molecule 1. It is also possible that chemokines such as
monocyte-chemoattractant protein 1, which is expressed by
adipocytes and the levels of which correlate with adiposity,
might contribute to monocyte recruitment and transmigration
of bone marrow-derived monocytes, leading to an increase in
white adipose tissue-resident macrophages, some of which
fuse to generate giant multinucleated cells (Xu et al., 2003).
These cells have been found to be increased in number and
shape in proportion to the body mass index, rising up to 60%
of the total number of adipose tissue components. The
proportional accumulation of macrophages could lead to an
increase in expression of proinflammatory molecules and
contribute to the inflammatory state in a significant way.
In addition, although lymphocytes are not a constituent of
the adipose tissue, there is often a close physical proximity
particularly in the lymph nodes, which are generally
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Figure 3. ‘‘Psoriasis and obesity’’: a two-compartment model of inflammation. This diagram depicts inflammation in the epidermis and dermis associated
with psoriasis vulgaris and likely inflammatory molecules that would be produced in adipose tissue of obese individuals. The model proposes that soluble
factors could enter the systemic circulation from either dermal or adipose tissue beds and, in addition, there could be direct exchange (diffusion) of factors
between dermal and adipose sites. The steps involved in blockade of insulin signaling and alteration of the production of adipokines by tumor necrosis
factor (TNF) are shown. DC, dendritic cell; TNFR, tumor necrosis factor receptor.
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surrounded by pericapsular adipose tissue. Data indicate the
presence of intriguing two-way paracrine interactions be-
tween lymphocytes and adjacent adipocytes (Pond, 2003).
Leptin in obesity
Leptin is a 16-kDa adipocyte-derived hormone discovered in
1994. Leptin, the product of the OB (obese) gene, exerts
biological actions through activation of its cognate receptors
that belong to the type 1 cytokine receptor superfamily (Zhang
et al., 1994). Binding of leptin to its receptor induces activation
of the Janus activated kinase signal transducers and activators
of transcription signal pathway, activating signal transducer
and activator of transcription-3 (Hegyi et al., 2004).
Circulating-leptin levels directly correlate with adipose
tissue mass and clinically can be used to reflect the
percentage of fat mass. Control of appetite is the primary role
of leptin. However, leptin is a key factor in regulating a wide
range of biological responses, including energy homeostasis,
hematopoiesis, neuroendocrine function, and immune re-
sponses (Auwerx and Staels, 1998; Fruhbeck et al., 1998;
Huang and Li, 2000; Otero et al., 2005). Thus, in addition to
being a hypothalamus modulator of food intake, body weight,
and fat stores, leptin exerts an important role in acute and
chronic inflammatory processes through regulation of cyto-
kine expression that modulates the balance of helper T-cell
types 1 and 2 (Juge-Aubry and Meier, 2002; Matarese et al.,
2005; Otero et al., 2006). Its receptor is expressed in various
tissues, including adipocytes, peripheral blood mononuclear
cells, endothelial cell fibroblasts, and injured KCs (Tartaglia,
1997; Eckel et al., 2005). The injured KCs show a behavior
similar to that of psoriatic hyperproliferative KCs, wherein
signal transducer and activator of transcription-3 activation
has also been reported (Eckel et al., 2005). Leptin protects T
lymphocytes from apoptosis and modulates T-cell prolifera-
tion, increasing the proliferation of naive T cells but reducing
the proliferation of memory T cells. Leptin modulates T-cell-
derived cytokine production and increases expression of the
activation markers CD25 and CD71 in CD4þ and CD8þ T
cells. In monocytes, leptin increases the expression of various
activation markers and upregulates phagocytosis and cytokine
production. In endothelial cells, leptin upregulates the
expression of adhesion molecules and induces oxidative
stress. Hence, leptin has a dual role in inflammation: it
activates monocytes and macrophages, potentiates produc-
tion of the proinflammatory cytokines TNF-a, IL-6 and IL-9,
and directs T-cell differentiation to a Th1 phenotype (Matarese
et al., 2002; La Cava et al., 2004; Otero et al., 2005). In
addition, leptin has been shown to stimulate keratinocyte
proliferation and angiogenesis (Bouloumie et al., 1998; Frank
et al., 2000; Cao et al., 2001; Stallmeyer et al., 2001; Murad
et al., 2003; Bernotiene et al., 2006).
In light of the above activities, leptin has been implicated
in the pathogenesis of immune-mediated inflammatory
diseases (IMIDs) such as type 1 diabetes, rheumatoid arthritis
(RA), inflammatory bowel disease, and psoriasis (Trayhurn,
2005). Hamminga et al. (2006) hypothesized that high levels
of leptin in obese patients may contribute to psoriasis by
releasing proinflammatory mediators. Body weight loss
has been reported to significantly decrease leptin levels
and improve insulin sensitivity (Ballantyne et al., 2005;
Hamminga, 2006), thus reducing the likelihood of develop-
ing metabolic syndrome and adverse cardiovascular diseases.
Leptin, in addition to the adipocytokines, may act as a link
between severe psoriasis and obesity by inducing or
augmenting inflammation. Indeed, recently elevated circulat-
ing-leptin levels were reported to be associated with psoriasis
(Wang et al., 2008). Moreover, hyperleptinemia was found
to be associated with psoriasis independent of female sex
and other conventional cardiovascular risk factors such
as obesity. Hyperleptinemia in psoriasis may contribute to
metabolic syndrome (Chen et al., 2008). In patients with
severe psoriasis, leptin and leptin-receptor expression were
found to be significantly higher than in patients with mild-to-
moderate psoriasis and in controls. A positive correlation
between leptin and leptin-receptor expression, serum leptin
levels and the disease duration was also observed (Cerman
et al., 2008). This finding links the chronic inflammation
status of psoriasis with metabolic disturbances. It seems that
high circulating-leptin levels in psoriasis may derive not only
from adipose tissue but also from an inflammatory process.
Adiponectin in obesity
Adiponectin is an adipocyte-specific secretory protein
abundantly present in the circulation. Adiponectin is com-
posed of a collagenous and a globular domain. Adiponectin
monomers trimerize through tight interactions in the colla-
genous domain. Trimers can then oligomerize. Both trimers
and oligomers are present in the circulation and might have
different effects on insulin sensitivity. Leukocyte elastase
released by activated immune cells cleaves the globular
domain of adiponectin, which might have activities distinct
from those of the full-length molecule.
Adiponectin induces the anti-inflammatory cytokines
IL-10 and IL-1 receptor antagonist in monocytes and
macrophages, while inhibiting the IL-6 level. A recent study
indicates that adiponectin inhibits TNF-a production and
TNF-a inhibits adiponectin production, thus antagonizing
each other’s function (Campfield et al., 1995). Adiponectin
also inhibits the biological activity of TNF-a. Inhibition of
NF-kB by adiponectin might explain at least part of these
effects (Wulster-Radcliffe et al., 2004). In endothelial cells,
adiponectin downregulates the expression of adhesion mole-
cules, ICAM-1 and vascular cell adhesion molecule 1, thus
contrasting the effect of TNF-a. Thus, adiponectin is consi-
dered to have overall beneficial effects (Figures 2 and 3).
Plasma levels of adiponectin are decreased in obesity, insulin
resistance, and type 2 diabetes. Low levels of adiponectin
are a strong independent predictor of elevated diabetes risk
in several populations (Spranger et al., 2003; Snijder et al.,
2006; Wannamethee et al., 2007), although its association
with incident vascular risk remains unclear (Sattar et al.,
2006). Hypoadiponectinemia is assumed to be closely
associated with the metabolic syndrome (Hulthe et al.,
2003). Plasma adiponectin levels in psoriasis are decreased
compared with healthy controls. It is assumed that aberrant
secretion of adipocytokines induces metabolic syndrome,
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which is a strong predictor of cardiovascular diseases (Eckel
et al., 2005). As regards its interaction with inflammation,
although earlier studies on anti-TNF-a therapy have sug-
gested increased serum adiponectin level with the improve-
ment of RA (Komai et al., 2007), much larger controlled trials
have not confirmed this (Popa et al., 2009). This suggests that
the links between adiponectin, inflammation, and CVD are
perhaps much more complex than originally determined and
more studies are required.
Other cytokines in obesity
In addition to leptin and adiponectin, adipocytes produce
TNF-a, IL-6, MCP-1, and other factors. Adipose tissue
macrophages produce TNF-a, IL-5, and MCP-1. Macrophage
products driven by granulocyte colony-stimulating factor may
even trigger adipocyte growth increase (Figure 3). Expression
analysis of macrophage and non-macrophage cell populations
isolated from adipose tissue demonstrates that adipose tissue
macrophages are responsible for almost all TNF-a expression
in the adipose tissue and significant amounts of inducible nitric
oxide synthase and IL-6 expression. Moreover, macrophages
present in the white adipose tissue of obese individuals
produce higher levels of proinflammatory chemokines com-
pared with those in lean persons. At the same time,
adiponectin production by adipocytes is reduced, possibly
through upregulated local TNF-a levels.
Although its ultimate source has not been identified, IL-1
receptor antagonist is markedly increased in the serum of
obese subjects, as in IL-18, IL-8, and macrophage inflamma-
tory protein 1(Esposito et al., 2002; Juge-Aubry et al., 2003).
So far, only one published study has investigated the Th-17
response as a potential marker of the inflammatory syndrome
in obesity (Sumarac-Dumanovic et al., 2009). It showed that
blood concentrations of the proinflammatory cytokines IL-17
and IL-23 are increased in obese women. This increase is
independent of the production of the proinflammatory
mediators leptin and macrophage migration inhibitory factor,
and is not directly associated with the increase in adipose
tissue mass or insulin resistance. Additional studies are
required to explore whether the IL-23/IL-17 cytokine axis
has a pathogenic role in the metabolic disturbances
associated with obesity.
INFLAMMATORY MOLECULES AND PATHWAYS IN
INSULIN RESISTANCE OR DIABETES MELLITUS
Insulin resistance is a condition in which normal amounts of
insulin are inadequate to produce a normal insulin response
from fat, muscle, and liver cells. Insulin resistance in fat cells
results in elevated hydrolysis of stored triglycerides leading to
elevated levels of free fatty acids in the blood. Insulin
resistance in muscle cells reduces glucose uptake and local
storage of glucose glycogen, whereas insulin resistance in
liver cells causes impaired glycogen synthesis and a failure
to suppress hepatic glucose production. Elevated blood
fatty acid levels further reduce muscle glucose uptake and
increase liver glucose production, thus contributing to
elevated blood glucose levels. It appears that inflammatory
mediators might be involved in the development of insulin
resistance. Cytokines and adipocytokines including TNF-a,
interleukin-6, leptin, and adiponectin (Fantuzzi, 2005; Well-
en and Hotamisligil, 2005) are increasingly recognized as
important regulators of both insulin sensitivity and inflamma-
tion, and a dysregulation of their levels and/or functions has
been shown in both obesity and other inflammatory diseases,
including psoriasis (Figures 1–3). Consistent with this, insulin
resistance was found in non-obese adults with psoriasis
(Ucak et al., 2006). Moreover, insulin resistance was found
to be significantly correlated with the psoriasis area and
severity index score (Boehncke et al., 2007).
TNF and insulin receptor signaling
TNF acts on adipocytes and muscle cells to induce insulin-
signaling defects by several ways, such as by impairing
insulin signaling through inhibition of the tyrosine kinase
activity of the insulin receptor; by activating peroxisome
proliferator-activated receptor-d that promotes epidermal
proliferation and modulates adipogenesis and glucose
metabolism; and by suppressing adiponectin secretion from
adipocytes, which is an important anti-inflammatory mole-
cule that also functions in regulating insulin sensitivity
(Gustafson et al., 2007; Wakkee et al., 2007; Romanowska
et al., 2008). Although the actions of TNF on adipocytes and
monocytes are complex with respect to metabolic regulation,
there is experimental evidence that TNF directly regulates
insulin secretion and disrupts lipid synthesis, which are the
central features of type 2 diabetes and obesity. This noted,
there is inconclusive evidence for the effects of therapeutic
TNF blockade on the insulin resistance of obesity.
IL-6 in diabetes
Recent studies suggest that IL-6 could be implicated in insulin
resistance and its complications (Ihle et al., 1995; Kroder
et al., 1996; Yudkin et al., 2000; Bastard et al., 2000, 2002).
The IL-6 receptor belongs to the class I family of cytokine
receptors, which uses Janus activated kinases as intracellular
signaling pathways (Ihle et al., 1995). Studies have shown an
interaction between cytokines and insulin signaling pathways
leading to decreased insulin signaling in the presence of
cytokines. The mechanisms involved are not clear, but there
is evidence suggesting the participation of protein kinases
and tyrosine phosphatase activation (Kroder et al., 1996) or
suppressor of cytokine signaling interaction with the insulin
receptor (Mooney et al., 2001; Lagathu et al., 2003; Rieusset
et al., 2004). Elevations of IL-6 plasma levels have been
linked to risk for type 2 diabetes independently of obesity and
insulin resistance (Wannamethee et al., 2007) and also
appear to predict an elevated risk of vascular events, at least
as strongly as C-reactive protein (CRP) (Danesh et al., 2008).
Leptin in diabetes
Leptin improves insulin sensitivity through activation of
adenosine monophosphate protein kinase, which controls
cellular concentrations of malonyl-CoA, thereby inhibiting
acetyl-CoA carboxylase (the enzyme involved in malonyl-
CoA transformation; Minokoshi et al., 2002). As a result, there
is a decrease of intracellular malonyl-CoA and a decline of
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lipogenesis associated with increased fatty-acid b-oxidation.
Interestingly, in generalized lipodystrophy, wherein adipose
tissue is nearly absent, leptin administration improves insulin
sensitivity (Oral et al., 2002). However, in common human
obesity, there are high circulating-leptin levels, suggesting
leptin resistance, and leptin administration has little or no
effect on insulin resistance. In fact, the leptin-signaling
pathway activates suppressor of cytokine signaling -3, which
might inhibit insulin signaling (Howard and Flier, 2006).
Therefore, while leptin deficiency very likely contributes to
insulin resistance when adipose tissue is lacking, leptin
resistance is a main feature of human obesity (Figure 3).
Furthermore, a recent study found that the leptin:adiponectin
ratio is a reliable measure of insulin resistance in non-diabetic
white adults as the gold standard measure of insulin resistance
(clamp insulin sensitivity index (M/I) value) or as currently
used methods, such as fasting insulin or homeostasis model
assessment for insulin sensitivity. Given that variations
between fasting insulin and postprandial leptin and adipo-
nectin levels tend to be small, leptin:adiponectin ratio might
also have potential value in assessing insulin sensitivity in the
non-fasted insulin state (Finucane et al., 2009).
Adiponectin in diabetes
Adiponectin is underexpressed in obese patients with insulin
resistance or type 2 diabetes, and in patients with coronary
heart disease. Similar to leptin, adiponectin enhances insulin
sensitivity through activation of adenosine monophosphate
protein kinase (Yamauchi et al., 2002). Adiponectin also
affects hepatic glucose production by decreasing the mRNA
expression of two essential gluconeogenesis enzymes:
phosphoenolpyruvate carboxykinase and glucose-6-phos-
phatase (Kadowaki and Yamauchi, 2005). It appears that
high-molecular weight adiponectin may be the most
insulin-sensitizing. Signal transduction pathways linking
inflammation and insulin resistance through inhibition of
phosphorylation of insulin signaling include NF-kB, c-Jun
N-terminal kinase, and endothelial reticulum stress, such as
obesity (Hotamisligil, 2003; Ozcan et al., 2004; Arkan et al.,
2005; Cai et al., 2005). Recent research shows that
endoplasmic reticulum is the cellular structure in adipocytes
that detects disrupted metabolic homeostasis, transmits the
signal and activates inflammatory signal-transduction systems
such as IkB kinase and c-Jun N-terminal kinase.
Other factors in diabetes
Chronic inflammation in psoriasis leads to increased IGF-II in
the skin and blood of psoriasis patients (Yoo et al., 2007).
IGF-II promotes epidermal proliferation and is also impli-
cated in promoting atherosclerosis, in modulating body fat
mass and lipid metabolism in mice, and is linked to diabetes
and hyperlipidemia in animal and human models (Zaina and
Nilsson, 2003). Immunocytes and KCs in psoriatic skin
produce angiogenic factors, such as VEGF, which promote
angiogenesis and endothelial cell activation. VEGF levels are
increased in plaques of psoriasis and serum concentration of
VEGF correlates with clinical severity of disease (Griffiths and
Barker, 2007). VEGF is also increased in hyperinsulinemic
states such as the metabolic syndrome, in which adipocytes
are its primary source (Cao, 2007). Therefore, hyperinsuli-
nemic states such as obesity and the metabolic syndrome
might promote susceptibility to psoriasis or exacerbate
existing psoriasis not only through their aforementioned role
in promoting and facilitating inflammation, but also through
increased and sustained levels of circulating VEGF. Decades
of chronic angiogenesis necessary to maintain the psoriasis
phenotype could also theoretically be related to cardiovas-
cular disorders through exhausting the pool of endothelial
precursor cells in the bone marrow, which are believed to
have a crucial role in maintenance of endothelial integrity,
function, and repair (Shantsila et al., 2007).
INFLAMMATORY MOLECULES AND PATHWAYS IN CVDs
The development of atherosclerotic vascular disease is a
progressive process in which inflammation has also been
implicated (Libby, 2000). Early intimal infiltration and acti-
vation of peripheral blood T cells followed by macrophage
infiltration are important events in the immune-mediated
pathogenesis of arteriosclerosis (Figure 4; Hansson and Libby,
2006). Transendothelial migration of T cells is a key early
step in atherosclerosis that is mediated by cell adhesion
molecules, such as ICAM-1 and vascular cell adhesion
molecule-1, on the vascular endothelium. Thereafter, macro-
phages accumulate releasing cytokines and enzymes, includ-
ing matrix metalloproteinases, which degrade the connective
tissue matrix. The next step is the formation of a more
advanced fibrous lesion that is characterized by the accu-
mulation of lipid-rich necrotic debris and smooth muscle cells.
These lesions normally have a fibrous cap composed of
smooth muscle cells and an extracellular matrix that surrounds
a lipid-rich necrotic core. The plaque, which is covered by a
fibrous cap, then gradually develops into an advanced and
complex lesion. Continuing inflammatory processes gradually
result in thinning of the fibrous cap to create a potentially
unstable plaque that can eventually rupture, with thrombosis
and clinical evidence of vascular occlusion (Ribatti et al.,
2008). Thus, inflammation is not only instrumental in the
development of human atheromatous plaques, but, signifi-
cantly, also has a crucial role in the destabilization of internal
carotid artery plaques, thus converting chronic atherosclerosis
into an acute thromboembolic disorder (Figure 4).
Hepatocytes and arterial smooth muscle cells are thought
to be primarily responsible for the production of secretory
phospholipase A2 group IIA, an acute-phase reactant, in
response to stimulation by cytokines (Hurt-Camejo et al.,
2001). Secretory phospholipase A2 group IIA is associated
with depressed plasma-cholesterol levels, altered lipoprotein
compositions, an enhanced ability to deliver cholesterol to
cells, and increased lipid depositions in aortic walls. This
mechanism is likely to contribute to the development of
hypocholesterolemia observed in patients with inflammatory
diseases. Secretory phospholipase A2 group IIA can also be
detected in the intima, adventitia, and media of the
atherosclerotic wall not only in developed lesions but also
in very early stages of atherosclerosis. Thus, secretory
phospholipase A2 group IIA appears to be an important link
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between the lipid and the inflammation hypothesis of
atherosclerosis. Furthermore, studies showing that therapies
that reduce inflammation may improve cardiovascular out-
come also support the role of inflammation (Ridker et al.,
2005).
Although the direct mechanisms of the association
between metabolic disturbances and unfavorable cardiovas-
cular events in psoriasis have yet to be elucidated, psoriasis
and atherosclerosis also have similar histological charac-
teristics involving T cells, macrophages, and monocytes.
In particular, the extravasation of leukocytes through the
endothelium is characteristic of both psoriatic and athero-
sclerotic plaques. Both unstable psoriatic and atherosclerotic
plaques also have an increased percentage of activated
T cells expressing a Th-1 pattern of cytokines, including
local and systemic expression of adhesion molecules, and
endothelins. Th-17 cells secreting IL-17 have an important
role in the pathogenesis of psoriasis and broadly activate
inflammation in a variety of organ systems (Arican et al.,
2005; Sabat et al., 2007). IL-17 is also elevated in the sera of
patients with unstable CVD (Hashmi and Zeng, 2006) and is
also preferentially expressed in animal models of aged
coronary arteries that are susceptible to ischemia (Csiszar
et al., 2003) Figure 4 shows some of the effects of cytokines
associated with psoriasis lesions and cardiovascular biology.
Effects of inflammation on coagulation and hypertension
are also shown in this figure and are discussed below.
Well-recognized CVD risk factors such as diabetes mellitus,
hypertension, and obesity (Preis et al., 2009) thus stem from
triggers that could be located in inflamed skin, adipose tissue,
or other inflamed site. In particular, elevated CRP most
probably reflects hepatic synthesis in elevated levels of IL-6 in
the circulation (Figures 2 and 4).
Recent genome-wide association studies have identified at
least 21 distinct gene loci that contribute to CVD (Arking and
Chakravarti, 2009). Interestingly, none of the identified genes
overlap with psoriasis susceptibility loci. Hence, these data
suggest that pathogenic links may be mediating more through
systemic inflammation and/or metabolic dysregulation asso-
ciated with inflammation.
Skin inflammation
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TNF
T cell
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or DCs
Chemokines
Flow
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TNF
IL-1
IL-6
Others
2— Chemokines promote
inward trafficking of T-cells
and DCs/macrophages
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Figure 4. ‘‘Cardiovascular risk factors’’: some potential cellular and molecular inflammatory pathways that could be triggered in the skin (left) and that would
then reach target tissues for cardiovascular risk (right). Cytokine (chemokine)-activated leukocytes (CAL) in cutaneous sites could either enter the skin tissue or
circulate after rolling on inflamed endothelial cells in psoriasis lesions. These cells and cytokines released into the systemic circulation, e.g., tumor necrosis
factor (TNF), IL-1, or IL-6, may alter the function of hepatocytes (a), vascular cells (b), atheroma (c), thrombus risk (d), or leukocyte physiology (e) to increase
cardiovascular risk factors or overt pathological pathways, as detailed in the right side of this figure. DCs, dendritic cells.
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INFLAMMATORY MOLECULES AND PATHWAYS IN
HYPERCOAGULATION
Factors that control coagulation include circulating factors
in blood (platelets and coagulation protein factors) and the
endothelial surface in target organs. Psoriasis has the
potential to affect both of these coagulation components.
Platelets
In psoriasis patients, evidence for an in vivo platelet
activation, which could contribute to the development of
thrombotic events, has been established (Kasperska-Zajac
et al., 2008). Spontaneous platelet hyperaggregability, mean
platelet volume, plasma levels of b-thromboglobulin, and
platelet factor 4, which are markers of platelet activation,
were found to be significantly higher in psoriasis patients
compared with that in controls. Interestingly, these markers,
as well as platelet aggregability, were significantly reduced
after psoriasis had cleared (Hayashi et al., 1985). Moreover,
platelet regeneration time, measured as malondialdehyde
recovery after aspirin ingestion, was significantly shorter in
psoriasis patients (Berrettini et al., 1985; Tamagawa-Mineoka
et al., 2008). Finally, P-selectin expression by platelets was
also increased in psoriasis patients, showing a direct correla-
tion with disease severity (Ludwig et al., 2004). Increased
platelet aggregation could be partly accounted for by the
increased release of arachidonic acid etherified in platelet
plasma membrane, as a response to platelet activators, as well
as by enhanced cyclooxygenase activity, which would result
in more thromboxane A2 availability (Vila et al., 1990, 1991).
On the other hand, activated platelets may exert a role in
psoriasis pathogenesis by favoring leukocyte rolling in the skin
microvasculature (Ludwig et al., 2004) and platelet-derived
12-hydroxyeicosatetraenoic acid may increase KC-DNA
synthesis (Kragballe and Fallon, 1986). These data suggest
that the homeostatic balance is deranged toward a prothrom-
botic state in psoriasis patients, which might be sustained by
platelet hyperactivity (Gisondi and Girolomoni, 2009).
In a recently published study, it was shown that platelet-
derived microparticles, which are released only by activated
platelets, were significantly increased in patients with
psoriasis compared with healthy controls, indicating that
blood platelets are in a state of activation in patients with
psoriasis (Tamagawa-Mineoka et al., 2009). Moreover, it was
found that plasma platelet-derived microparticle levels were
closely correlated with disease severity in psoriasis (psoriasis
area and severity index); therefore, the authors suggested
that platelet-derived microparticles may be a useful indicator
of disease severity. It is thought that platelet-derived micro-
particles can increase leukocyte adhesion to the endothelium
and promote leukocyte activation by modulating leukocyte–
leukocyte and leukocyte–endothelial cell interactions
(Wagner and Burger, 2003). Several kinds of chemokines
that are secreted by platelets after activation (Wagner and
Burger, 2003; von Hundelshausen and Weber, 2007) are
also detected in psoriatic plaques (Nickoloff et al., 2007).
Taken together, these observations suggest that platelet-
derived mediators may contribute to leukocyte recruitment
to psoriatic skin lesions.
Coagulation protein factors
Inflammatory markers that are shed into the bloodstream in
psoriatic and/or obese patients, such as TNF-a, IL-1, IL-6, can
induce synthesis and release of acute-phase proteins, i.e. CRP
and serum amyloid A, by the liver and increase the
expression of cellular adhesion molecule on endothelial cells
(e.g., ICAM-1, vascular cell adhesion molecule), which is
required for the migration of leukocytes out of the circulation
into the inflamed tissue, and potentially modulate prothrom-
bic factors, thus increasing plasminogen activator inhibitor-1
and decreasing tissue plasminogen activator (Barton, 1996).
In addition, adipokines also interface with thrombosis, as
thrombospondin-1 is synthesized by adipocytes. Thrombo-
spondin-1 activates transforming growth factor-b, which
regulates plasminogen activator inhibitor-1 production also
by adipocytes as well as hepatocytes and endothelial cells
(Fain et al., 2004). Thus, plasminogen activator inhibitor-1
levels are increased in obesity and in patients with metabolic
syndrome; this prothrombotic state could contribute to
thrombus formation and therefore to CAD (Figures 1 and 4).
In addition, in cell culture, both CRP and serum amyloid A
promote a number of proinflammatory cellular effects,
including monocyte recruitment, activation of complement,
and stimulation of cellular adhesion molecule and cytokine
expression (Pasceri et al., 2000; Woollard et al., 2002;
Han et al., 2004). Serum amyloid A is also closely related to
high-density lipoprotein and may displace apolipoprotein A-I
from high-density lipoprotein to inhibit cholesterol efflux and
reverse cholesterol transport (Banka et al., 1995). However,
these direct actions in cell culture have been questioned in
recent years (Pepys and Hirschfield, 2003). A key idea in the
cardiovascular risk is that even low-level systemic inflamma-
tion can serve as a permissive environment for thrombo-
embolism and overt cardiovascular morbidity and mortality.
The association between inflammation and thrombosis
was recently reinforced by a new placebo control study. In
apparently healthy persons, with normal low-density lipo-
protein-cholesterol levels but elevated CRP, the occurrence
of symptomatic venous thromboembolism was significantly
reduced in the rosuvastatin-treated group as compared with
the placebo group (Albert et al., 2001). Rosuvastatin is known
to have anti-inflammatory effects in addition to lipid-lowering
effects (Glynn et al., 2009). However, this study showed that
rosuvastatin is able to prevent thromboembolism probably
because of its anti-inflammatory effects and independent
from its lipid-lowering effects.
INFLAMMATORY MOLECULES AND PATHWAYS IN
HYPERTENSION
All components of the renin–angiotensin system are found in
adipose tissue (Karlsson et al., 1998; Gorzelniak et al., 2002;
Figures 1 and 3). In fact, adipose tissue is the major extrahepatic
source of angiotensinogen, enabling the rise in its plasma
concentration in obese individuals (Engeli et al., 2005).
Angiotensinogen is the precursor of angiotensin-I, which, after
conversion to angiotensin-II, has a major role in blood pressure
regulation. Angiotensin II increases thirst, promotes salt
retention by the kidney, causes vasoconstriction, enhances
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the release of catecholamines from nerves and the adrenal
gland, and stimulates T-cell proliferation (Nataraj et al., 1999;
Jackson et al., 2004). Angiotensin II was also found to enhance
inflammation and the development of atherosclerosis (Kim and
Iwao, 2000). Moreover, angiotensinogen mRNA expression is
increased in visceral fat (Dusserre et al., 2000; Van Harmelen
et al., 2000), which might partially explain the relationship
between systemic hypertension and obesity in the metabolic
syndrome and also provide insight into why weight loss
commonly leads to blood pressure reduction (Moore et al.,
2005). However, it is still unclear whether angiotensin II
secreted by adipose tissue has an important systemic hemody-
namic (vasoconstriction) and/or non-hemodynamic (stimula-
tion of expression of adhesion molecules, macrophage
chemoattractant protein-1, and macrophage colony stimulating
factor in endothelial cells) role (Tham et al., 2002). Although
angiotensinogen from adipose tissue has been shown to have a
role in hypertension in rodent models, this has yet to be shown
in humans. Moreover, it is clear that obesity is a major risk
factor for hypertension and many relevant studies have now
examined and confirmed this, as recently reviewed (Wild and
Byrne, 2006; Figure 4).
A recent interesting study showed that peripheral blood
T cells are activated to produce TNF-a, IFN-g, and to express
tissue-homing receptors upon angiotensin II infusion (Guzik
et al., 2007). Blockade of TNF-a by etanercept normalized
the blood pressure and vascular O2
  production in angio-
tensin II-infused animals. Another important finding in that
study was the localization of T cells to the perivascular fat.
Thus, another potential explanation of the common coexis-
tence of visceral obesity and hypertension is that the increase
in visceral adipose tissue leads to accumulation of perivas-
cular fat, which in turn serves as a reservoir for activated
effector T cells, which promote vascular dysfunction and
hypertension.
CONCLUSIONS AND FUTURE PROSPECTIVE FOR
PREVENTION OF CO-MORBIDITIES
To conclude, psoriasis is a prototypical T-cell-mediated
inflammatory disease. It is characterized by activation of
antigen-presenting cells, and activation and expansion of
Th-1 and Th-17 T cells. Th-1 and Th-17 inflammatory
cytokines are elevated in the skin and blood of patients with
psoriasis and are critical to recruiting T cells to the skin and
joints, promoting angiogenesis, and epidermal hyper-
proliferation. At the same time, these inflammatory mediators
have pleiotropic effects on diverse processes such as
angiogenesis, insulin signaling, adipogenesis, lipid metabo-
lism, and immune cell trafficking (Figure 4). Therefore, the
metabolic aspects of chronic Th-1 and Th-17 inflammation in
psoriasis have the potential to impact other conditions such
as obesity, diabetes, thrombosis, and atherosclerosis. Con-
versely, inflammatory molecules and hormones produced in
conditions such as obesity, diabetes, and atherosclerosis may
influence the pathogenesis of psoriasis by promoting a
proinflammatory state, which increases the susceptibility to
the development of psoriasis or the severity of established
psoriasis (Figure 2).
Psoriasis has widened its scope as an IMID showing
a potential for systemic co-morbidity (Nestle et al., 2009).
In view of the chronic nature of inflammation in psoriasis
and the lingering process of the development of its related
co-morbidities, the most important question is whether long-
term control of psoriasis could prevent, reverse, or attenuate
these co-morbidities. Therefore, effective treatment moda-
lities should aspire to benefit beyond direct disease target.
In another chronic systemic inflammatory disease, RA, which
is also associated with an increased risk for CVD, treatment
with methotrexate has been linked to a reduction in CVD
events and mortality (Krause et al., 2000; Prodanovich et al.,
2005). Similarly, there is suggestive evidence of lower
CVD risk with TNF blockade in patients with RA (Dixon
et al., 2007). Together with such observations, biomarkers of
CVD risk (e.g., high CRP) that measure ‘‘inflammation’’ are
clearly associated with increased cardiovascular risk. One
recent study (JUPITER; Albert et al., 2001) sought to
determine whether low-grade inflammation in patients with
elevated CRP values, but ‘‘normal’’ lipid levels, could be
modulated by a statin and/or reduce the overall cardio-
vascular morbidity. The JUPITER study targeted apparently
healthy men and women with low levels of low-density
lipoprotein-cholesterol, but with elevated high-sensitivity
CRP levels that were randomized to treatment with rosuvas-
tatin versus placebo. Statins are proposed to have anti-
inflammatory effects in addition to lipid-lowering effects
(Albert et al., 2001). The study was stopped early, as the
group receiving rosuvastatin had a reduced incidence of
major cardiovascular events (Ridker et al., 2008). This study
has been interpreted as showing a functional link between
systemic inflammation and cardiovascular risk, but others
had argued that the main effect of the JUPITER study could
entirely be predicted on the basis of reduction in low-density
lipoprotein-cholesterol level (Sattar and Hingorani, 2009).
Resolution of this issue must thus be addressed by future trials
in normal individuals, but the increased cardiovascular risk
associated with frank inflammatory diseases stands as
independent evidence of potential links between inflamma-
tion and cardiovascular risk.
A question for the future is whether long-term treatment of
psoriasis will alter the pathophysiology of co-morbid conditions
in primary sites, e.g., reduction in fat-cell metabolism, so
clearly linked to inflammation and thus reduction of
the overall risk through the integrated pathway discussed
in this review. Biological treatments for psoriasis, e.g. anti-TNF-
a (etanercept) or anti-p-40 (ustekinumab), have also been
shown to reduce CRP in short-term trials (Sattar et al., 2007) and
might thus have an overall beneficial systemic effect. It is
suggested that for effective management of psoriasis and its
related co-morbidities, we need an integrated approach
targeting both cutaneous and systemic inflammation. Poten-
tially, effective treatment of co-morbidities, in particular obesity,
may also decrease psoriasis disease activity and severity.
Careful studies are now needed to determine the impact of
treating ‘‘cutaneous’’ disease in psoriasis on systemic co-
morbidities. We must also determine whether direct targeting
of co-morbid disease states, e.g. obesity, hyperlipidemia,
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insulin resistance, or other factors, can improve skin and
cardiovascular functions.
At present, there is no independent biomarker of increased
cardiovascular risk in psoriasis patients. The N-terminal pro-
brain natriuretic peptide (B-type natriuretic peptides) is a newly
identified marker for incipient cardiac risk (Di Angelantonio
et al., 2009). There is some evidence for the N-terminal pro-
brain natriuretic peptide to be higher in RA and to be reduced
by anti-inflammatory therapy (Peters et al., 2010); therefore, it
would be interesting to investigate it in psoriasis patients.
Clearly, good clinical management of metabolic and cardio-
vascular health is indicated for psoriasis patients. A recent
consensus report provides some new guidance for management
of CVD risk and advocates using more conservative thresholds
of conventional biomarkers in starting treatment (Friedewald
et al., 2008). We think similar attention should be drawn to
obesity, smoking, and other life-style-controllable factors,
particularly as each of these elements is found to be higher in
psoriatic patients (Naldi et al., 2005).
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